BioNTech SE (BNTX)

NASDAQ: BNTX · IEX Real-Time Price · USD
-0.44 (-0.40%)
At close: Jun 8, 2023, 4:00 PM
-0.01 (-0.01%)
After-hours: Jun 8, 2023, 7:44 PM EDT
Market Cap 26.26B
Revenue (ttm) 13.28B
Net Income (ttm) 6.78B
Shares Out 240.99M
EPS (ttm) 26.89
PE Ratio 3.95
Forward PE 9.89
Dividend n/a
Ex-Dividend Date Jun 2, 2022
Volume 642,723
Open 109.84
Previous Close 109.41
Day's Range 108.46 - 110.00
52-Week Range 100.08 - 188.99
Beta 0.21
Analysts Buy
Price Target 167.31 (+53.54%)
Earnings Date May 8, 2023

About BNTX

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 10, 2019
Employees 4,530
Stock Exchange NASDAQ
Ticker Symbol BNTX
Full Company Profile

Financial Performance

In 2022, BioNTech SE's revenue was 17.31 billion, a decrease of -8.78% compared to the previous year's 18.98 billion. Earnings were 9.43 billion, a decrease of -8.34%.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for BNTX stock is "Buy." The 12-month stock price forecast is $167.31, which is an increase of 53.54% from the latest price.

Price Target
(53.54% upside)
Analyst Consensus: Buy
Stock Forecasts


BioNTech says drug from OncoC4 partnership shows promise in mid-stage trial

BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc was shown to shrink tumours in close to 30% of participants in a mid-stage lung can...

6 days ago - Reuters

BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO

MAINZ, Germany, and ROCKVILLE, Maryland, USA, June 2, 2023 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”), today announced positive preliminary data from the ong...

6 days ago - GlobeNewsWire

BioNTech is proceeding with COVID-shot in line with WHO guidance

Germany's BioNTech said it was on track to introduce a COVID-19 shot by the early fall in the northern hemisphere that is adapted to currently dominant virus variants in line with recommendations by t...

2 weeks ago - Reuters

Report of new COVID wave in China pushes shares of vaccine makers higher

Dr. Kavita Patel, fmr. White House health policy director, joins 'Fast Money' to discuss the latest reports of a possible uptick of COVID cases in China, the immunity situation in the country, and the...

Other symbols: JNJMRNAPFE
2 weeks ago - CNBC Television

BioNTech Revenue Falls. Why the Stock Is Climbing Anyway.

BioNTech's first-quarter revenue falls from a year earlier as demand for Covid-19 vaccines wanes but still tops analysts' estimates.

1 month ago - Barrons

BioNTech's stock jumps 4.3% premarket after earnings fall but top estimates

BioNTEch SE's stock BNTX rose 4.3% in premarket trade Monday, after the German biotech posted far stronger-than-expected first-quarter earnings, even as profit and revenue tumbled on lower demand for ...

1 month ago - Market Watch

BioNTech Announces First Quarter 2023 Financial Results and Corporate Update

COVID-19 vaccine franchise focused on vaccine adaptation readiness ahead of the fall season and advancing next generation vaccine candidates and combinations BioNTech and partner OncoC4 plan to start ...

1 month ago - GlobeNewsWire

FDA authorizes Pfizer-BioNTech booster for young kids with compromised immune systems

The U.S. Food and Drug Administration late Friday authorized Pfizer Inc. PFE and BioNTech SE BNTX COVID-19 bivalent vaccine for immunocompromised children. The shot, which would be a fourth dose in mo...

Other symbols: PFE
1 month ago - Market Watch

BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023

MAINZ, Germany , April 24, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2023 on Monday, May 8th, 2023. BioN...

1 month ago - GlobeNewsWire

BioNTech enters cancer drug partnership with DualityBio

BioNTech SE BNTX, +1.63% said Monday it has entered a partnership with Shanghai-based Duality Biologics to acclereate the development of antibody-drug conjugates to treat patients with cancer and auto...

2 months ago - Market Watch

BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors

MAINZ, Germany and SHANGHAI, China, April 3, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”), a clinical-stage biotech company focusing on the disc...

2 months ago - GlobeNewsWire

BioNTech Announces New ADS Repurchase Program

MAINZ, Germany, March 28, 2023 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that it has entered into a new share repurchase program (the “Program”), purs...

2 months ago - GlobeNewsWire

BioNTech stock slumps on worse-than-expected drop in revenue

Don't Miss: Valley of Hype: The culture that built Elizabeth Holmes WATCH HERE:

2 months ago - Yahoo Finance

BioNTech shares slip on gloomy Covid vaccine sales outlook

The shares initially fell by 6.4% to an intraday low of $119.98 a share before recovering most of those losses in late morning trading.

2 months ago - CNBC

BioNTech Is Ripe For A Rebound In 2023

BioNTech (NASDAQ: BNTX) got a substantial boost from the pandemic and its mRNA vaccine, developed with Pfizer (NYSE: PFE). The stock has seen a substantial correction since then due to slowing COVID s...

2 months ago - MarketBeat

BioNTech Stock Is Falling. Blame the Covid Vaccine Outlook.

The German biotech that partnered with Pfizer to develop a Covid-19 vaccine expects fewer vaccinations and lowered levels of boosting this year.

2 months ago - Barrons

BioNTech stock falls as earnings beat expectations, but show falling demand for COVID-19 vaccines

The U.S.-listed shares of BioNTech SE BNTX, -0.92% fell 2.7% in premarket expectations, as profit and revenue beat expectations but fell from a year ago due to lower demand for COVID-19 vaccines, and ...

2 months ago - Market Watch

BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

Conference call and webcast scheduled for March 27 at 8:00 am ET (2:00 pm CET)

2 months ago - GlobeNewsWire

BioNTech inks deal with OncoC4 to develop cancer treatments

BioNTech SE BNTX, -1.76% will pay $200 million to the privately held OncoC4 Inc. as part of a deal to develop and commercialize OncoC4's monoclonal antibody treatment that is being tested in several c...

2 months ago - Market Watch

BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications

MAINZ, Germany and ROCKVILLE, Maryland, USA, March 20, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”), a clinical-stage biopharmaceutical company dedicated to the discovery ...

2 months ago - GlobeNewsWire

FDA updates authorization of BioNTech, Pfizer's bivalent booster for young children

The Food and Drug Administration on Tuesday said children between the ages of 6 months and 5 years old can now get a booster dose of BioNTech BNTX and Pfizer's PFE COVID-19 bivalent vaccine. The third...

Other symbols: PFE
3 months ago - Market Watch

BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023

MAINZ, Germany , March 13, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2022 on Monday, Marc...

3 months ago - GlobeNewsWire

BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel

JERUSALEM, Israel, March 1, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) announced that the Company and the Weizmann Institute of Science (“Weizmann Institute”) signed a Memorandum of ...

3 months ago - GlobeNewsWire

BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility

MAINZ, Germany, February 2, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced construction completion of the Company's first proprietary plasmid DNA manufacturing facility...

4 months ago - GlobeNewsWire

Mergers and Acquisitions in 2023 Off To A Strong Start

Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $...

4 months ago - MarketBeat